Table 3

Percentage of participants with rSBA titres8 and128 and GMTs before and after vaccination
Group Timing N %8 [95% CI] %128 [95% CI] GMT [95% CI]
rSBA-MenA
ACWY-TT M0 305 95.1 [92.0, 97.2] 89.5 [85.5, 92.7] 330.7 [285.8, 382.7]
M1 323 100 [98.9, 100] 99.7 [98.3, 100] 4944.6* [4451.5, 5492.5]
Y1 354 99.7 [98.4, 100] 99.4 [98.0, 99.9] 2084.9* [1888.3, 2302.0]
Y2 338 99.7 [98.4, 100] 99.1* [97.4, 99.8] 1326.8* [1197.7, 1469.7]
Y3 322 100 [98.9, 100] 99.1* [97.3, 99.8] 1238.4* [1126.0, 1361.9]
Men-PS M0 101 87.1 [79.0, 93.0] 80.2 [71.1, 87.5] 227.8 [162.1, 320.2]
M1 112 100 [96.8, 100] 100 [96.8, 100] 2190.1 [1857.5, 2582.2]
Y1 113 100 [96.8, 100] 99.1 [95.2, 100] 1099.1 [931.6, 1296.7]
Y2 102 99.0 [94.7, 100] 96.1 [90.3, 98.9] 698.9 [561.2, 870.4]
Y3 104 100 [96.5, 100] 94.2 [87.9, 97.9] 596.9 [488.5, 729.3]
rSBA-MenC
ACWY-TT M0 324 78.1 [73.2, 82.5] 53.1 [47.5, 58.6] 84.1 [68.5, 103.4]
M1 341 99.7 [98.4, 100] 99.7 [98.4, 100] 10073.7* [8699.9, 11664.5]
Y1 353 99.7 [98.4, 100] 97.2 [94.9, 98.6] 1848.6 [1620.3, 2109.2]
Y2 345 99.4 [97.9, 99.9] 96.2 [93.6, 98.0] 1162.0 [1013.1, 1332.9]
Y3 337 99.1 [97.4, 99.8] 92.9 [89.6, 95.4] 870.3 [757.1, 1000.4]
Men-PS M0 113 85.0 [77.0, 91.0] 49.6 [40.0, 59.1] 114.1 [80.3, 162.0]
M1 114 100 [96.8, 100] 98.2 [93.8, 99.8] 6545.6 [5047.5, 8488.4]
Y1 115 99.1 [95.3, 100] 95.7 [90.1, 98.6] 1876.5 [1400.7, 2514.0]
Y2 112 98.2 [93.7, 99.8] 92.0 [85.3, 96.3] 1229.4 [876.4, 1724.7]
Y3 109 99.1 [95.0, 100] 93.6 [87.2, 97.4] 1124.8 [812.3, 1557,6]
rSBA-MenW-135
ACWY-TT M0 327 75.5 [70.5, 80.1] 58.4 [52.9, 63.8] 93.0 [74.6, 116.0]
M1 340 99.7 [98.4, 100] 99.4 [97.9, 99.9] 8576.5* [7614.9, 9659.5]
Y1 356 99.7 [98.4, 100] 99.4* [98.0, 99.9] 2993.5* [2618.8, 3421.9]
Y2 346 99.4 [97.9, 99.9] 98.6* [96.7, 99.5] 1984.6* [1757.1, 2241.4]
Y3 336 99.7* [98.4, 100] 98.8* [97.0, 99.7] 2109.2* [1842.5, 2414.5]
Men-PS M0 109 81.7 [73.1, 88.4] 61.5 [51.7, 70.6] 115.3 [81.6, 162.9]
M1 114 100 [96.8, 100] 100 [96.8, 100] 2969.5 [2439.4, 3614.9]
Y1 117 100 [96.9, 100] 94.9 [89.2, 98.1] 699.9 [569.3, 860.4]
Y2 111 90.1 [83.0, 94.9] 81.1 [72.5, 87.9] 319.1 [228.0, 446.5]
Y3 105 86.7 [78.6, 92.5] 80.0 [71.1, 87.2] 332.8 [224.4, 493.8]
rSBA-MenY
ACWY-TT M0 330 92.7 [89.4, 95.3] 80.0 [75.3, 84.2] 310.0 [261.2, 367.9]
M1 340 100 [98.9, 100] 99.7 [98.4, 100] 10315.2* [9317.1, 11420.2]
Y1 355 100 [99.0, 100] 99.7 [98.4, 100] 4207.1* [3767.3, 4698.3]
Y2 345 99.7 [98.4, 100] 99.1* [97.5, 99.8] 3042.1* [2692.2, 3437.5]
Y3 338 99.7 [98.4, 100] 99.4 [97.9, 99.9] 2567.3* [2288.6, 2879.8]
Men-PS M0 113 92.9 [86.5, 96.9] 77.9 [69.1, 85.1] 282.8 [209.9, 380.8]
M1 114 100 [96.8, 100] 100 [96.8, 100] 4573.7 [3863.9, 5413.9]
Y1 116 100 [96.9, 100] 98.3 [93.9, 99.8] 1386.5 [1104.2, 1740.9]
Y2 111 99.1 [95.1, 100] 94.6 [88.6, 98.0] 850.2 [667.5, 1082.9]
Y3 108 99.1 [94.9, 100] 97.2 [92.1, 99.4] 848.0 [682.6, 1053.5]

ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.

Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.

N = number of participants with available results.

% = percentage of participants with titres within the specified range.

GMT = geometric mean titre.

95% CI = 95% confidence interval.

M0 = pre-vaccination blood sample taken at Month 0; M1 = post-vaccination blood sample taken at Month 1 (ATP immunogenicity cohort); Y1 = post-vaccination blood sample taken at Year 1 (ATP cohort for persistence Year 1); Y2 = post-vaccination blood sample taken at Year 2 (ATP cohort for persistence Year 2); Y3 = post-vaccination blood sample taken at Year 3 (ATP cohort for persistence Year 3).

*Statistically significantly higher value in the ACWY-TT group compared to the Men-PS group in exploratory analyses.

Borja-Tabora et al.

Borja-Tabora et al. BMC Infectious Diseases 2013 13:116   doi:10.1186/1471-2334-13-116

Open Data